<DOC>
	<DOCNO>NCT01059344</DOCNO>
	<brief_summary>Asacol™ 4.8 g/day ( 800 mg tablet ) statistically significant effective induce clinical endoscopic remission 6 week treatment compare placebo subject active ulcerative colitis ( UC ) .</brief_summary>
	<brief_title>Efficacy Safety Asacol™ 4.8 g/Day ( 800 mg Tablets ) Treatment Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>( 1 ) Male nonpregnant , nonlactating female , 18 year age old . ( 2 ) Documented diagnosis UC disease extend least 15 cm anal verge . ( 3 ) Active UC define : ( ) modify UCDAI score 410 ( b ) sigmoidoscopy component score ≥ 2 ( c ) rectal bleed component score ≥ 1 ( 4 ) Ability subject participate fully aspects clinical trial . ( 5 ) Written informed consent must obtain document . 1 . Severe UC define follow criterion : ³6 bloody stool daily one following : 1. oral temperature &gt; 37.8°C &gt; 100.0°F 2. pulse &gt; 90/min 3. hemoglobin &lt; 10 g/dL 2 . Previously fail treatment mesalazine dose &gt; 2.0 g/day . 3 . Current relapse last &gt; 6 week opinion investigator . 4 . Treatment 5ASA dose &gt; 2.0g/day within 1 week prior randomisation 5 . Treatment systemic rectal steroid within 4 week prior randomization . 6 . Treatment immunosuppressant within 6 week prior randomization . 7 . Treatment infliximab biologics within 3 month prior randomization . 8 . Treatment systemic antibiotic UC within 7 day prior randomization . 9 . Treatment probiotic within 7 day prior randomization . 10 . Treatment antidiarrheal within 7 day prior randomization . 11 . Treatment nicotine patch within 7 day prior randomization . 12 . Received investigational drug within 30 day prior randomization . 13 . History colectomy partial colectomy . 14 . History definite dysplasia colonic biopsy . 15 . Crohn 's disease . 16 . Known bleed disorder . 17 . Immediate significant risk toxic megacolon . 18 . Hypersensitivity salicylates , aspirin , sulfasalazine 5ASA . 19 . Serum creatinine &gt; 1.5 time upper limit normal range . 20 . AST , ALT , total bilirubin alkaline phosphatase &gt; 2 time upper limit normal range . 21 . Serious underlying disease UC opinion investigator may interfere subject 's ability participate fully study . 22 . History alcohol drug abuse opinion investigator may interfere subject 's ability comply study procedure . 23 . Stools positive clostridium difficile . 24 . Pregnant lactating woman . 25 . Prior enrolment current study receive study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Mesalamine</keyword>
	<keyword>Asacol</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>induction therapy</keyword>
	<keyword>acute disease</keyword>
	<keyword>mild moderate</keyword>
	<keyword>Active Ulcerative Colitis ( mild moderate )</keyword>
</DOC>